Exact Sciences Corporation

Good morning. My name is Rob and I will be your conference operator today. At this time, I'd like to welcome everyone to the Exact Sciences fourth quarter 2022 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again press the star one. Thank you, Megan Jones, Senior Director, Investor Relations. You may begin your conference.

Thanks, Rob. Thank you for joining us for ExactScience's fourth quarter 2022 conference call. On the call today are Kevin Conroy, the company's Chairman and CEO, and Jeff Elliott, our Chief Financial Officer and Chief Operating Officer. Everett Cunningham, our Chief Commercial Officer, will also be available for questions. ExactScience issued a news release earlier this afternoon detailing our fourth quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may have material differences from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release, and descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website. I'll now turn the call over to Kevin.

The strength of our foundation supporting the best brands in cancer diagnostics puts us in a leading position to continue delivering innovative cancer tests, consistent revenue growth, and profitability. We are using this platform to help prevent cancer detected earlier and guide treatment for more patients globally. Achievements in 2022 that help strengthen our leadership include surpassing 12 million cumulative people tested for cancer, including 10 million with Cologuard. Expanding our global network of ordering healthcare professionals to more than 350,000. Growing core revenue, 380 million year over year. Becoming adjusted EBITDA profitable in the fourth quarter. Completing enrollment of Blue Sea, our pivotal study to support our next generation Cologuard and colon cancer blood tests, and generating evidence for our multi-cancer early detection and molecular residual disease tests. Over the past decade, we've built a high-quality platform to deliver advanced cancer tests at scale. We've invested heavily in our people, lab infrastructure, technology systems, clinical evidence, brands, and customer experience. This platform is fueling efficient growth for our current tests, and over time it will fuel the next wave of novel cancer diagnostics. Our health system customers employ most U.S. healthcare professionals and seek to improve the quality of care while reducing costs. They are incentivized to focus on preventive care, including cancer screenings. Today, many phases of staff shortage lead to a trend of more in-home service as Cologuard. Advanced cancer testing. In advanced cancer testing, health systems continue to ask for fewer partners to meet their needs. A complete range of high-quality, impactful tests, broad insurance coverage, EMR integration, and data-sharing capabilities. Exact Sciences is uniquely positioned to deliver on these needs because we have the broadest offering of innovative cancer tests, patient-focused services, EMR integration capabilities, and payer relationships. This year, we'll increase adoption of Cologuard and Noctite DX, create an even better customer experience, and advance our key pipeline programs in colorectal cancer, multi-cancer early detection, and molecular residual disease. Jeff will now discuss our financial results and outlook for 2023. Thanks, Kevin.